Evaluation of Therapeutic Response of Patients with Erectile Dysfunction

Background: All three phosphodiesterase-5 (PDE5) inhibitors for the treatment of the erectile dysfunction have similar efficacy and toxicity profiles. Sildenafil and vardenafil have similar molecular structures, but tadalafil is structurally different, which is reflected in its pharmacokinetic profile. These pharmacokinetic differences among the PDE5 inhibitors may underlie patient preference, an important and emerging aspect of ED therapy. Aim: The study is conducted to show and compare efficacy and safety of the three PDE-5 inhibitors and to assess patientʹs preference in the treatment of erectile dysfunction. Itʹs still unknown which of the three PDE-5 inhibitors is used the most. Methods: Study is conducted during two years on 53 patients with erectile dysfunction. Evaluation is done after 8 weeks of initial treatment followed by a 1- week washout period and then continued thetherapy with the second and third medicine by the same protocol. Results: After three months of the treatment, patientsʹ preference was as follows: 33 patients (62%) choose tadalafil, 13 patients(24%)choose sildenafiland 7 patients (14%) choose vardenafil. Choice of PDE-5 for initial treatment was a significant predictor for substitution from one drug to another. Conclusion: Frequency of sexual intercourse (occasional use or regular therapy)and personal experience will determine the medicine of choice. When chooring medicine,attentien should be paid to the beginning of its functioning, duration and possible interaction with food.